VSTM

Verastem Inc

8.18

Nov 13 • 3:59 PM ET -0.26 (-3.08%)

7.99

Aftermarket • 7:30 PM ET -0.19 (-2.32%)

Healthcare Biotechnology USA Small NASD

Peers: ERAS RVMD BBOT IMRX CELC KURA ORIC ELVN ZNTL CRDF

| Held by: VTI XBI IWM VXF IWO VTWO BBP FESM IDNA IWC

Scroll to Statements

Index	RUT
Market Cap	1.03B
Enterprise Value	986.56M
Income	-178.90M
Sales	100.30M
Book/sh	0.11
Cash/sh	1.37
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	102
IPO	Jan 27, 2012

P/E	-
Forward P/E	-
PEG	-
P/S	10.28
P/B	76.51
P/C	5.97
P/FCF	-
EV/EBITDA	-
EV/Sales	9.84
Quick Ratio	1.91
Current Ratio	1.93
Debt/Eq	12.73
LT Debt/Eq	11.51
Option/Short	Yes / Yes

EPS (ttm)	-1.85
EPS next Y	-2.04
EPS next Q	-0.53
EPS this Y	34.71%
EPS next Y	-3.44%
EPS next 5Y	11.44%
EPS past 3/5Y	12.90% 10.63%
Sales past 3/5Y	- 10.80%
EPS Y/Y TTM	54.01%
Sales Y/Y TTM	649.65%
EPS Q/Q	45.19%
Sales Q/Q	113.59%
Earnings	Nov 05 AMC
EPS/Sales Surpr.	-56.45% -9.63%

Insider Own	9.46%
Insider Trans	-0.62%
Inst Own	75.63%
Inst Trans	7.93%
ROA	-88.02%
ROE	-471.16%
ROIC	-141.64%
Gross Margin	86.11%
Oper. Margin	-193.73%
Profit Margin	-178.38%
SMA20	-12.40%
SMA50	-3.60%
SMA200	29.92%
Trades

Shs Outstand	126.02M
Shs Float	114.09M
Short Float	17.24%
Short Ratio	5.76
Short Interest	19.67M
52W High	10.82 -24.41%
52W Low	3.43 138.48%
Volatility	6.64% 6.99%
ATR (14)	0.66
RSI (14)	41.63
Beta	0.47
Rel Volume	0.50
Avg Volume	3.42M
Volume	1,721,146

Perf Week	-2.73%
Perf Month	-11.38%
Perf Quarter	13.93%
Perf Half Y	89.35%
Perf YTD	5.96%
Perf Year	0.86%
Perf 3Y	28.21%
Perf 5Y	-78.29%
Perf 10Y	-45.47%
Recom	1.00
Target Price	17.22
Prev Close	8.44
Price	8.18
Change %	-3.08%

Consensus

Strong Buy

Avg. Price Target

$17.22

Implied Upside

+110.5%

Analysts12incl. previous ratings

Rating Distribution11 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 17, 2026	Initiated	WWolfe Research	Outperform
Mar 12, 2026	Resumed	BBTIG Research	Buy	$19	+132.3%
Feb 04, 2026	Initiated	HH.C. Wainwright	Buy	$18	+120.0%
Oct 16, 2025	Resumed	CCantor Fitzgerald	Overweight
Apr 10, 2025	Initiated	JJefferies	Buy	$15	+83.4%
Mar 24, 2025	Reiterated	HH.C. Wainwright	Buy	$7 → $10	+22.2%
Dec 31, 2024	Reiterated	BBTIG Research	Buy	$13 → $20	+144.5%
Sep 30, 2024	Initiated	GGuggenheim	Buy	$13	+58.9%
Nov 21, 2023	Resumed	BBTIG Research	Buy	$27	+230.1%
Sep 27, 2023	Initiated	RB. Riley Securities	Buy	$21	+156.7%
Jun 15, 2023	Upgrade	MMizuho	Neutral → Buy	$24 → $36	+340.1%
Sep 07, 2022	Resumed	AAlliance Global Partners	Buy	$6	-26.7%
Apr 29, 2022	Resumed	CCantor Fitzgerald	Overweight	$6 → $5	-38.9%
Apr 14, 2022	Initiated	RRBC Capital Mkts	Outperform	$5	-38.9%
Mar 09, 2022	Initiated	TTruist	Buy	$6	-26.7%
Jul 01, 2021	Initiated	AAlliance Global Partners	Buy	$6	-26.7%
May 24, 2021	Upgrade	BBTIG Research	Neutral → Buy	$8	-2.2%
Jun 20, 2019	Downgrade	BBTIG Research	Buy → Neutral
May 10, 2019	Downgrade	RRaymond James	Outperform → Mkt Perform
Jul 13, 2018	Initiated	BBTIG Research	Buy	$17	+107.8%

Nov-05-26 09:09PM	Verastem Misses As Co-Pack Sales Stall, But VS-7375 Data And A $250 Million Raise Reset The Investment Case (Earnings Whispers) -10.34%
04:38PM	Verastem: Q3 Earnings Snapshot (Associated Press)
03:01PM	Verastem Oncology Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates (Business Wire)
Nov-02-26 06:30AM	Verastem Oncology to Participate in Upcoming November Investor Conferences (Business Wire)
Oct-28-26 09:40PM	Verastem Must Prove Its Commercial Rebound Is Real As G12D Hopes Lift The Stock (Earnings Whispers)
07:30AM	Loading…
Oct-22-26 07:30AM	Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026 (Business Wire) +9.23%
Oct-15-26 05:00PM	VSTM Stock Clocks Best Day In 11 Months After Positive Cancer Drug Trial Update And Multiple Price-Target Hikes (Stocktwits) +19.71% -6.28%
12:22PM	Verastems KRAS inhibitor posts wins in mPDAC, mCRC and NSCLC (Clinical Trials Arena)
Oct-14-26 11:00AM	Verastem cancer drug shows early promise in small study (BioPharma Dive)
09:46AM	Verastem Is Getting a New CEO, $250 Million, and a Shot at Another Cancer Drug (Barrons.com)
07:42AM	Verastem Has Positive Early Cancer Data And $250M In New Funding: What VSTM Investors Need To Know (Stocktwits)
06:04AM	Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants (Business Wire)
06:01AM	Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan (Business Wire)
06:00AM	VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed) (Business Wire)
Oct-11-26 10:17PM	Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates The Weeks Biotech Watchlist (Stocktwits)
04:02PM	Loading…
Oct-05-26 04:02PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-02-26 07:30AM	Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026 (Business Wire)
Sep-28-26 04:10PM	Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
08:00AM	KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034 (PR Newswire)
Sep-25-26 08:00AM	Nuvectis' In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It's Not Even Their Lead Asset (FinanceWire)
Sep-24-26 08:30AM	Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting (Business Wire)
Sep-08-26 07:30AM	Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers (Business Wire)
Sep-02-26 07:30AM	Verastem Oncology to Participate in Upcoming September Investor Conferences (Business Wire) +5.39%
Aug-07-26 01:10AM	Verastem Inc (VSTM) (Q2 2026) Earnings Call Highlights: Strong Revenue Rebound and Strategic ... (GuruFocus.com) +14.04%
Aug-06-26 04:19PM	Verastem: Q2 Earnings Snapshot (Associated Press)
04:01PM	Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates (Business Wire)
Jul-28-26 04:01PM	Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer (Business Wire)
Jul-23-26 07:30AM	Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026 (Business Wire)
Jul-22-26 04:01PM	Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer (Business Wire)
Jul-02-26 04:30PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +9.76%
04:01PM	Loading…
Jun-23-26 04:01PM	VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors (Business Wire) -8.55%
Jun-17-26 07:30AM	Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer (Business Wire)
Jun-16-26 04:01PM	Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer (Business Wire)
Jun-15-26 04:01PM	Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program (Business Wire)
Jun-03-26 08:10PM	VSTM Stock Climbs After-Hours As FDA Grants Fast Track To Lung Cancer Drug Retail Eyes The Next Keytruda (Stocktwits) +6.63%
May-27-26 07:30AM	Verastem Oncology to Present at Jefferies Healthcare Conference (Business Wire)
May-26-26 07:30AM	Verastem Oncology Appoints Michael P. Bailey to its Board of Directors (Business Wire)
May-12-26 07:30AM	Verastem Oncology to Present at Upcoming Investor Conferences (Business Wire) -5.12%
May-08-26 07:30AM	On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer (Business Wire) -13.60%
May-07-26 05:16PM	Verastem: Q1 Earnings Snapshot (Associated Press) -5.82%
04:01PM	Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates (Business Wire)
Apr-30-26 07:30AM	Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI FAKZYNJA CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
Apr-23-26 07:30AM	Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026 (Business Wire)
Apr-10-26 07:00AM	Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI FAKZYNJA Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Womens Cancers (Business Wire) -5.01%
Apr-02-26 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-17-26 06:03PM	Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026 (Business Wire)
04:44PM	Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI FAKZYNJA (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers (Business Wire)
Mar-05-26 12:03AM	Verastem Inc (VSTM) Q4 2025 Earnings Call Highlights: Transition to Commercial Stage and ... (GuruFocus.com) +5.85%
Mar-04-26 08:48PM	Verastem Q4 Earnings Call Highlights (MarketBeat)
05:10PM	Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:20PM	Verastem: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
Feb-18-26 07:30AM	Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 (Business Wire)
Feb-17-26 12:00PM	What Makes Verastem (VSTM) a New Buy Stock (Zacks)
Feb-16-26 01:02AM	Verastem Touts 50%+ Sales Growth for LGSOC Launch, Teases RAMP 301 and KRAS G12D Catalysts (MarketBeat)
Feb-05-26 11:42AM	Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results (Zacks) -7.51%
Feb-04-26 08:00AM	Here Are Wednesdays Top Wall Street Analyst Research Calls: AES Corp, Airbnb, Cloudflare, Devon Energy, Levi Strauss, Lumentum, PayPal, and More (24/7 Wall St.) +7.78%
07:30AM	Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers (Business Wire)
Jan-30-26 10:19AM	$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors (PR Newswire)
Jan-12-26 04:01PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.73%
Jan-07-26 03:33PM	Revolution Medicines stock surges over 20% on potential AbbVie acquisition (Investing.com) +11.05%
Dec-29-25 04:01PM	Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (Business Wire)
Dec-15-25 04:01PM	Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth (Business Wire) -6.80%
Nov-25-25 07:30AM	Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference (Business Wire)
Nov-14-25 07:57AM	TEM Continues to Strengthen Its Genomics Leadership With New Products (Zacks) -6.84%
12:41AM	Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Nov-13-25 04:07PM	Verastem Oncology Announces Proposed Public Offering of Common Stock (Business Wire)
Nov-05-25 07:30AM	Verastem Oncology to Present at Upcoming Investor Conferences (Business Wire)
Nov-04-25 04:02PM	Verastem Inc (VSTM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Rising ... (GuruFocus.com) -20.10%
08:40AM	Verastem (VSTM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:40AM	Verastem: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
Nov-03-25 12:00PM	Verastem (VSTM) Upgraded to Buy: Here's Why (Zacks)
Oct-29-25 11:57AM	Verastem, Inc. (VSTM) Delivers Positive Preliminary Data for VS-7375 in Mutant Solid Tumors Treatment (Insider Monkey)
Oct-28-25 11:35AM	3 Cancer-Focused Stocks Showing Strong Pipeline Progress (Zacks)
Oct-23-25 04:01PM	Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors (Business Wire)
09:55AM	Verastem (VSTM) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
07:30AM	Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025 (Business Wire)
Oct-21-25 10:00AM	Best Momentum Stocks to Buy for Oct. 21 (Zacks)
06:39AM	New Strong Buy Stocks for Oct. 21: NEM, AS and More (Zacks)
Oct-20-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Verastem (VSTM) is a Great Choice (Zacks) -13.02%
09:55AM	Wall Street Analysts Think Verastem (VSTM) Could Surge 68.11%: Read This Before Placing a Bet (Zacks)
Oct-19-25 04:15AM	Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma (Business Wire)
Oct-07-25 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-19-25 12:00PM	Verastem (VSTM) Upgraded to Buy: Here's What You Should Know (Zacks) -5.14%
Sep-16-25 01:13PM	Top Biotech Picks for 2025: BTIG Research Highlights Potential Winners (Investing.com) -7.03%
Aug-27-25 07:00AM	Verastem Oncology to Present at Upcoming Investor Conferences (Business Wire)
Aug-17-25 03:22AM	Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects (Insider Monkey)
Aug-13-25 04:29PM	Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer (Business Wire)
Aug-07-25 06:40PM	Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +19.93%
05:36PM	Verastem: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
Aug-05-25 05:55PM	Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-31-25 10:00AM	Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline (Zacks)
Jul-29-25 07:30AM	Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 (Business Wire)
Jul-24-25 07:30AM	Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer (Business Wire)
Jul-23-25 09:26AM	High-Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds (PR Newswire)
Jul-14-25 07:42AM	Verastems avutometinib combination shows 31% ORR in ovarian cancer trial (Clinical Trials Arena) +5.87%
Jul-11-25 04:12PM	Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology (Business Wire)
Jul-08-25 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Paterson Dan	President and CEO	Nov 03 '26	Sale	9.60	1,299	12,470	651,413	Nov 05 07:53 PM
Paterson Dan	President and CEO	Oct 01 '26	Sale	8.00	44,121	352,968	652,712	Oct 02 05:15 PM
Calkins Daniel	Chief Financial Officer	Oct 01 '26	Sale	8.00	2,566	20,528	123,781	Oct 02 05:15 PM
Dan Paterson	Officer, Director	Oct 01 '26	Proposed Sale	8.00	44,121	353,047		Oct 01 06:55 PM
Calkins Daniel	Chief Financial Officer	Sep 21 '26	Sale	7.70	55	424	118,014	Sep 23 08:10 PM
Paterson Dan	President and CEO	Aug 03 '26	Sale	5.81	1,302	7,565	589,940	Aug 05 04:37 PM
Gagnon Robert E.	Director	Jul 23 '26	Proposed Sale	5.89	31,924	188,032		Jul 23 04:32 PM
Gagnon Robert E.	Director	Jun 25 '26	Proposed Sale	4.21	21,492	90,481		Jun 25 04:01 PM
Paterson Dan	President and CEO	Jun 22 '26	Sale	4.18	20,871	87,241	591,242	Jun 24 04:45 PM
Calkins Daniel	Chief Financial Officer	Jun 22 '26	Sale	4.18	4,089	17,089	117,238	Jun 24 04:44 PM
Dan Paterson	Officer, Director	Jun 22 '26	Proposed Sale	4.18	20,871	87,241		Jun 22 07:50 PM
Gagnon Robert E.	Director	May 27 '26	Proposed Sale	4.36	20,103	87,649		May 27 04:47 PM
Paterson Dan	President and CEO	May 04 '26	Sale	5.82	806	4,691	612,113	May 06 04:01 PM
Paterson Dan	President and CEO	Feb 04 '26	Sale	6.69	970	6,489	612,919	Feb 05 04:10 PM
Dan Paterson	Officer	Jan 12 '26	Proposed Sale	7.16	5,039	36,069		Jan 14 05:15 PM
Dan Paterson	Officer, Director	Jan 12 '26	Proposed Sale	7.16	10,321	73,851		Jan 14 05:13 PM
Paterson Dan	President and CEO	Jan 12 '26	Sale	7.16	10,321	73,898	400,104	Jan 14 05:12 PM
Calkins Daniel	Chief Financial Officer	Jan 12 '26	Sale	7.16	5,039	36,079	104,719	Jan 14 05:11 PM
Calkins Daniel	Chief Financial Officer	Dec 24 '25	Sale	7.86	80	629	109,758	Dec 29 12:24 PM
Stuglik Brian M	Director	Dec 16 '25	Sale	9.14	592	5,411	101,147	Dec 18 04:47 PM
Paterson Dan	President and CEO	Dec 16 '25	Sale	9.14	393	3,592	410,425	Dec 18 04:46 PM
Gagnon Robert E.	Director	Dec 16 '25	Sale	9.14	283	2,587	41,678	Dec 18 04:45 PM
Paterson Dan	President and CEO	Dec 10 '25	Sale	10.07	2,000	20,140	412,818	Dec 12 05:06 PM
Paterson Dan	President and CEO	Dec 11 '25	Sale	10.00	2,000	20,000	410,818	Dec 12 05:06 PM
Paterson Dan	President and CEO	Dec 05 '25	Sale	10.61	2,000	21,220	418,818	Dec 09 05:03 PM
Paterson Dan	President and CEO	Dec 08 '25	Sale	10.50	2,000	21,000	416,818	Dec 09 05:03 PM
Paterson Dan	President and CEO	Dec 09 '25	Sale	10.25	2,000	20,500	414,818	Dec 09 05:03 PM
Paterson Dan	Officer	Dec 09 '25	Proposed Sale	10.27	7,790	80,003		Dec 09 03:11 PM
Paterson Dan	President and CEO	Dec 02 '25	Sale	10.32	2,000	20,640	424,818	Dec 04 04:54 PM
Paterson Dan	President and CEO	Dec 04 '25	Sale	10.00	2,000	20,000	420,818	Dec 04 04:54 PM
Paterson Dan	President and CEO	Dec 03 '25	Sale	10.00	2,000	20,000	422,818	Dec 04 04:54 PM
Paterson Dan	President and CEO	Nov 28 '25	Sale	10.79	2,000	21,580	428,818	Dec 01 04:40 PM
Paterson Dan	President and CEO	Dec 01 '25	Sale	10.39	2,000	20,780	426,818	Dec 01 04:40 PM
Paterson Dan	President and CEO	Nov 26 '25	Sale	10.32	2,000	20,640	430,818	Dec 01 04:40 PM
Bunn Paul A.	Director	Nov 21 '25	Option Exercise	3.27	6,250	20,438	8,333	Nov 25 05:35 PM
Bunn Paul A.	Director	Nov 21 '25	Sale	10.00	6,250	62,500	2,083	Nov 25 05:35 PM
Kauffman Michael	Director	Nov 21 '25	Sale	10.00	8,550	85,500	8,666	Nov 25 05:34 PM
Paterson Dan	President and CEO	Nov 25 '25	Sale	10.00	2,000	20,000	432,818	Nov 25 05:32 PM
Paterson Dan	President and CEO	Nov 24 '25	Sale	10.00	2,000	20,000	434,818	Nov 25 05:32 PM
Paterson Dan	President and CEO	Nov 21 '25	Sale	10.00	2,000	20,000	436,818	Nov 25 05:32 PM
Kauffman Michael	Board Member	Nov 21 '25	Proposed Sale	9.81	8,550	83,876		Nov 21 04:20 PM
Bunn Paul A.	Board Member	Nov 21 '25	Proposed Sale	9.81	6,250	61,312		Nov 21 04:10 PM

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

PresidentMr. Daniel W. Paterson

Chief Financial OfficerMr. Daniel Calkins

Ph.D.Dr. Michael Glen Kauffman M.D.

Co-Founder & Chair of Scientific Advisory BoardDr. Robert A. Weinberg Ph.D.

Ph.D.Dr. Michelle Detwiler M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

VSTM

Verastem Inc

Upgrade your Finviz experience

All the Features.
Half the Price.